Andres Sosa, MD
Pulmonary Disease · Miami, FLNPI 1902951742
Payments from drug & device makers
Across 927 payments — averaging $98.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$63K
- Regeneron Healthcare Solutions, Inc.$9K
- Intuitive Surgical$3K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$1K
- plus $12K from 45 others
What the payments were for
- Speaking & faculty fees$64,59771%
- Travel & lodging$3,5724%
- Food & beverage$22,52225%
- Education$1700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$36,696
- DUPIXENT$8,619
- Da Vinci Surgical System$2,200
- NUCALA$1,111
- Pulmonx Endobronchial Valve EBV$762
- Monarch Platform$275
- UPTRAVI$225
- OPSUMIT$225
- AREXVY$125
- Adempas$118
- TYVASO$117
- Arikayce$116
How this compares
$90,860 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 52 | $690,091 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 555 | $393,212 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 388 | $185,529 |
| Breo ElliptaFluticasone/Vilanterol | 270 | $122,201 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $115,623 |
| Pirfenidone | 37 | $115,301 |
| NucalaMepolizumab | 29 | $107,288 |
| Dupixent PenDupilumab | 24 | $92,397 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 108 | $78,259 |
| Arnuity ElliptaFluticasone Furoate | 173 | $36,924 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 61 | $32,572 |
| SymbicortBudesonide/Formoterol Fumarate | 107 | $29,767 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 55 | $24,813 |
| EliquisApixaban | 24 | $17,913 |
| Atrovent HfaIpratropium Bromide | 17 | $7,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta | $62,592 | $848,7091,426 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $1,478 | $729,895124 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,803 | $132,840270 claims |
| Grifols USA, LLCProlastin C | $88 | $115,62312 claims |
| PfizerEliquis | $86 | $17,91324 claims |
| MerckAsmanex | $260 | $1,14711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Miami
- James KrainsonMiami$11.7M
- Lourdes BoschMiami$4.2M
- Manuel SuarezMiami$3M
- Eduardo VasquezMiami$1.9M
- Manuel Hernandez-AbrilMiami$1.9M
- Jaime AvecillasMiami$1.6M
- Trishul SiddharthanMiami$1.2M
- Shirin ShafazandMiami$969K
- Yoel BritoMiami$802K
- Maria Tupayachi OrtizMiami$716K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.